Navigation Links
Reliant Pharmaceuticals Announces the Filing of Registration Statement on Form S-1 For an Initial Public Offering
Date:12/20/2007

LIBERTY CORNER, N.J., Aug. 10 /PRNewswire/ -- Reliant Pharmaceuticals, Inc. today announced that it has filed a registration statement on Form S-1 with the Securities and Exchange Commission for an initial public offering of its common stock. The registration statement contemplates that Reliant will sell newly issued common stock and that certain stockholders may sell a portion of their current holdings of Reliant's common stock.

Goldman, Sachs & Co. and Merrill Lynch & Co. will act as the joint lead managers and joint book-runners for the proposed offering. The public offering will be made only by means of a prospectus which, when available, may be obtained by writing or calling one of the underwriters: Goldman, Sachs & Co., 85 Broad Street, New York, NY 10004, Attention: Prospectus Department (Tel: 212-902-1171) or Merrill Lynch & Co., 4 World Financial Center, New York, NY 10080, Attention: Prospectus Department (Tel: 212-449-1000).

A registration statement relating to the proposed sale of these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time the registration statement becomes effective. This release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Reliant Pharmaceuticals, Inc.

Reliant Pharmaceuticals is a pharmaceutical company that specializes in the development, commercialization and marketing of prescription therapeutic products. Reliant currently markets four cardiovascular products in the United States and focuses on promoting its products to targeted primary care and specialty physicians, as well as selected hospitals and
'/>"/>

SOURCE Reliant Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
2. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
3. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
4. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
5. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
6. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
7. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
8. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
9. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
10. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
11. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 30, 2014   Wyle has been ... Lifecycle Mission Support Services (FILMSS) contract awarded by ... the terms of the contract, Wyle will provide ... Field, Calif. In particular, Wyle will provide program ... projects on the International Space Station and collaborative ...
(Date:7/30/2014)... 30, 2014 Yuma Regional Cancer ... complementary therapies brings comprehensive cancer care to Yuma, ... Regional Cancer Center has officially opened. A Mayo ... includes services such as open, semi-private and private ... Cancer Society Resource Center, hematology, rehabilitation center, a ...
(Date:7/30/2014)... July 30, 2014  AtheroNova Inc. (OTCBB: AHRO), ... development of compounds to safely regress atherosclerotic plaque ... that its partner, CardioNova, has accomplished first dosing ... with AtheroNova,s lead compound, AHRO-001.  This Phase 1b ... Phase 1 safety trial completed in February 2014, ...
(Date:7/30/2014)... Adding to their already extensive selection of ... – Buy 2 of any Weighing Boats or Dishes ... technicians looking for durable and reliable weighing products to ... applications including weighing liquids, solid, or granulated samples. ... hexagonal, square, aluminum weighing, and standard boats. Aluminum weighing ...
Breaking Biology Technology:Wyle Wins NASA's Fully Integrated Lifecycle Mission Support Services Contract 2Sate-of-the-Art Yuma Regional Cancer Center Officially Opens 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 2AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 3AtheroNova Announces Milestone with Initiation of Phase 1b Clinical Trial of AHRO-001 4Weighing Boat Promotion Now Available at Pipette.com, Major Pipette Distributor 2
... AMSTERDAM, November 30 Biopharmaceutical company Kiadis,Pharma ... in its,multinational registration clinical trial with ATIR(TM). The study ... after one,year following an allogeneic stem cell transplantation with ... an allogeneic,stem cell transplantation but without having a matched ...
... , ... Yongxin Pharmaceuticals, Inc. (OTC Bulletin Board: CYXN; ,China Yongxin,Pharmaceuticals, ... pharmaceuticals in Northeastern China, today announced it has,completed preparation ... , The Chinese government recently ...
... NOVATO, Calif., Nov. 30 BioMarin Pharmaceutical Inc. (Nasdaq: ... Drug Administration (FDA) has granted orphan drug designation for ... Lambert Eaton Myasthenic Syndrome (LEMS). 3,4-DAP has previously ... in October 2009, the Committee for Medicinal Products for ...
Cached Biology Technology:Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 2China Yongxin Pharmaceuticals Inc. to Distribute Medicines on the Essential Drug List 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4
(Date:7/30/2014)... humans figured out how to create colors, nature had ... wings of many different hues, for example. Now scientists ... environmentally friendly way to make colored plastics. Their paper ... of materials rather than dyes, to produce color ... , N. Asger Mortensen, Anders Kristensen and colleagues point ...
(Date:7/30/2014)... professor from Wayne State University,s College of Engineering ... Science Foundation for the project, "Nanoparticle-directed synthesis of ... Science Foundation, nanotechnology is the creation and utilization ... properties and functions. A major bottleneck in scaling ... that connect different functional materials into one device. ...
(Date:7/30/2014)... therapies for spinal cord injury (SCI), traumatic brain injury ... great deal has been learned over the past 30 ... factors that regulate axon growth, but this large body ... therapeutics. Prof. Lemmon and his team from University of ... root causes, but a consensus is emerging that one ...
Breaking Biology News(10 mins):NSF grant to Wayne State supports new concept for manufacturing nanoscale devices 2
... Eucalyptus trees - or gum trees as they are know - ... system and depositing it their leaves and branches., Scientists from CSIRO ... Nature Communications . "The eucalypt acts as a hydraulic ... and draw up water containing the gold. As the gold is ...
... prominence as research reagents in modern biological science labs, ... lot can differ significantly from the next, in terms ... loss of countless hours of research, to say nothing ... antigen is a substance that stimulates the production of ...
... Clemson University scientists are working to determine how ... for neurological disorders like Tuberous Sclerosis Complex (TSC). ... growth of tumors in the brain and other vital ... and cognitive impairment that may arise from the abnormal ...
Cached Biology News:There's gold in them thar trees 2The hitchhiker antigen: Cause for concern? 2Clemson University study points to possible treatment for brain disorders 2
Rabbit Anti-Human Secretory Carrier Membrane Protein 2 (SCAMP2 Polyclonal AntibodyOther Sub-Family: not assigned-Other Applications: Western Blot...
Parathyroid Hormone Receptor 2 [PTHR2]...
... a proprietary high-performance desalting resin, exclusive to ... characteristics compared to other commercially available resins. ... of protein can be processed, providing exceptional ... salts and other small molecules ( ...
... member of the caudal-related homeobox family, is ... proliferation and differentiation in intestinal epithelial cells. ... cells towards the phenotype of differentiated villus ... of the phenotype. Clone CDX2-88 reacts with ...
Biology Products: